Physician profile
Seth H Berk
NPI 1326073677
$2,872.16
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $654 · 2020: $41.11 · 2023: $1,386 · 2024: $792.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,075 · Food and Beverage: $85.41 · Education: $17.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,075.00 |
| Food and Beverage | $85.41 |
| Education | $17.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,426.99 | 2019-2023 | |
| Glaxosmithkline, LLC. | $725.00 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $123.88 | 2019 | |
| Genentech USA, INC. | $80.84 | 2019-2024 | Polivy, Columvi, Phesgo |
| Amgen INC. | $75.36 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $56.02 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $51.16 | 2019 | |
| Novartis Pharmaceuticals Corporation | $50.24 | 2019 | |
| Abbvie INC. | $47.87 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $31.01 | 2019 | |
| Genzyme Corporation | $28.53 | 2019 | |
| Merck Sharp & Dohme LLC | $26.69 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $17.02 | 2024 | Libtayo |
| Puma Biotechnology, INC. | $14.74 | 2019 | |
| Celgene Corporation | $14.53 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $14.22 | 2019 | |
| Array Biopharma INC | $14.14 | 2019 | |
| Seagen INC. | $12.84 | 2019 | |
| Gilead Sciences, INC. | $12.50 | 2019 | |
| Rigel Pharmaceuticals, INC. | $12.49 | 2019 | |
| Foundation Medicine, INC. | $12.48 | 2019 | |
| Karyopharm Therapeutics INC. | $12.45 | 2020 | |
| Pfizer INC. | $11.16 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$54,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seth Berk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.